Heghine Khachatryan: World Federation of Hemophilia Is Far More Than An Organization
Heghine Khachatryan, Editor-in-Chief of Hemostasis Today, Head of Hemophilia and Thrombosis Center at Yeolyan Hematology and Oncology Center, reposted from WFH on LinkedIn:
”WFH’s work consistently reinforces a critical truth:
bleeding disorders are not only medical conditions — they are issues of health equity, gender equity, and human rights.
-For clinicians, WFH represents knowledge, standards, and professional growth
-For patients, it provides voice, visibility, and dignity
– For health systems, it offers a sustainable model for organizing rare disease care.
World Federation of Hemophilia (WFH) is far more than an organization — it is a global movement that has fundamentally transformed the lives of people living with hemophilia and other inherited bleeding disorders worldwide.
As 2025 comes to a close, WFH’s impact is particularly evident in several key areas:
• increasing global awareness of hemophilia and bleeding disorders,
• addressing the long-standing underdiagnosis of bleeding disorders in women and girls,
• strengthening continuous medical education for healthcare professionals,
• advancing laboratory standards, clinical guidelines, and evidence-based care, and
• expanding equitable access to safe and effective treatment.
With gratitude for WFH’s global leadership, collaboration, and unwavering commitment to patient-centered care.”
Qutoing World Federation of Hemophilia‘s post:
”As 2025 comes to a close, the World Federation of Hemophilia is celebrating a year of meaningful progress for people with hemophilia and Bleeding Disorders around the world.
Thanks to our global community, partners, and volunteers, this year saw important milestones, from expanding diagnosis and care to strengthening humanitarian aid and advancing treatment standards.
Read more.
Wishing our community a bright start to 2026, we look forward to connecting with you in Malaysia for the WFH 2026 World Congress!”
Stay updated with Hemostasis Today.
-
Jul 14, 2026, 19:35Daratumumab in Difficult-to-Treat iTTP: Updated Results from the International DarTTP Study
-
Jul 14, 2026, 17:1610 Posts Not To Miss from ISTH 2026, Part 3
-
Jul 14, 2026, 15:27Dianne E Van Der Wal: Celebrating Scientific Contributions at ISTH 2026
-
Jul 14, 2026, 15:13Alfonso Tafur: RIETE Registry Analysis Supports More Equitable Approaches to VTE Care
-
Jul 14, 2026, 15:03Heghine Khachatryan: Phase III Trial Results Support BAFF-R Inhibition in Corticosteroid-Refractory ITP
-
Jul 14, 2026, 14:51Nathan Connell: ISTH 2026 Highlights the Power of Lifelong Collaboration
-
Jul 14, 2026, 14:42Wolfgang Miesbach: VOYAGER1 Highlights Progress Toward Injection-Free Care in Hemophilia A
-
Jul 14, 2026, 12:08Elvira Grandone: Finding the Right LMWH Dose for Pregnant Patients Suffering From DVT
-
Jul 14, 2026, 12:05Eloïse Laouenan: From Washington to Paris – Join GETBO at ISTH 2026